Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease | MicrobiomeTrials← Back to trialsNCT07113743
Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease
ENROLLING_BY_INVITATIONPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2025-09-10Est. Completion: 2028-09-01
Enrollment target: 10 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
GranulomaGranulomatous Disease, ChronicLeukocyte DiseaseGenetic Disease, X-LinkedGenetic Disease, Inborn
The research goal of this study is to obtain CD34+ hematopoietic stem cells (HSC) from peripheral blood and/or bone marr…
Bethesda, United States
Chronic Granulomatous DiseaseInfection
Background:
CGD is caused by a gene mutation. For people with CGD, their cells cannot kill germs well, so they can get …
Bethesda, United StatesEst. completion Jul 1, 2027